Mechanism of Extracellular Histone-Induced Endothelial Dysfunction Leading to Sepsis-Induced Acute Respiratory Distress Syndrome
Abstract
Sepsis-induced acute respiratory distress syndrome (ARDS) is an independent risk factor for mortality in critically ill septic patients. However, effective therapeutic targets are still unavailable due to the lack of understanding of its unclear pathogenesis. With increasing understanding in the roles of circulating histones and endothelial dysfunction in sepsis, we aimed to investigate the mechanism of histone-induced endothelial dysfunction leading to sepsis-induced ARDS and to provide experimental support for histone-targeted treatment of sepsis-induced ARDS.
Methods First of all, in vitro experiments were conducted. Human umbilical vein endothelial cells (HUVEC) were stimulated with gradient concentrations of histones to explore for the optimal stimulation concentration in vitro. Then, HUVEC were exposed to histones at an optimal concentration with or without resatorvid (TAK-242), a selective inhibitor of Toll-like receptor 4 (TLR4), for 24 hours for modeling. The cells were divided into 4 groups: 1) the blank control group, 2) the blank control+TAK-242 intervention group, 3) the histone stimulation group, and 4) the histone+TAK-242 intervention group. HUVEC apoptosis was determined by flow cytometry, VE-Cadherin expression in endothelial cells was determined by Western blot, and the integrity of adhesion connections between endothelial cells was evaluated with confocal fluorescence microscopic images. Male C57BL/6 mice aged 6-8 weeks and weighing 22-25 g were used for the in vivo experiment. Then, the mice were given cecal ligation and puncture (CLP) as well as histone injection at 50 mg/kg via the tail vein for sepsis modeling. The experimental animals were divided into 6 groups: 1) the blank control group, 2) the blank control+TAK-242 intervention group, 3) the CLP model group, 4) the CLP+TAK-242 intervention group, 5) the histone model group, and 6) the histone+TAK-242 intervention group. After 24 h, the concentrations of serum interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) were determined using ELISA kits. Western blot was performed to determine the expression of vascular endothelial (VE)-cadherin in the lung tissue. Hematoxylin and eosin (HE) staining was performed to observe the pathological changes in the lung tissue of the mice. Evans Blue was injected via the tail vein 30 min before the mice were sacrificed. Lung tissue was collected after the mice were sacrificed. Then, the concentrations of Evans blue dye per unit mass in the lung tissue from mice of different groups were evaluated, the rates of pulmonary endothelial leakage were calculated, and the integrity of the pulmonary endothelial barrier was evaluated.
Results The results of the in vitro experiment showed that, compared with those of the control group, HUVEC apoptosis was significantly increased under histone stimulation (P<0.05), the expression of VE-cadherin was decreased (P<0.05), and the integrity of adherens junctions between endothelial cells was damaged. TAK-242 can significantly inhibit histone-induced HUVEC apoptosis and VE-cadherin expression reduction and maintain the integrity of adherens junctions between endothelial cells. According to the findings from the in vivo experiments, in mice with CLP-induced and histone-induced sepsis, TAK-242 effectively alleviated the increase in serum concentrations of IL-6 and TNF-α, reduced the downregulation of VE-cadherin expression in the lung tissue (P<0.05), decreased endothelial permeability of the lung vessels, and improved pathological injury in the lung tissue.
Conclusion By binding to TLR-4, histone decreases VE-cadherin expression on the surface of vascular endothelial cells, disrupts the integrity of intercellular adherens junctions, and triggers pathological damage to lung tissue. Using TLR-4 inhibitors can prevent sepsis-induced ARDS in histone-induced sepsis.
Keywords: Sepsis, Acute respiratory distress syndrome, Endothelial dysfunction, Extracellular histone, Toll-like receptor 4
Full Text:
PDFReferences
GORMAN E A, O'KANE C M, MCAULEY D F. Acute respiratory distress syndrome in adults: diagnosis, outcomes, long-term sequelae, and management. Lancet, 2022, 400(10358): 1157–1170. doi: 10.1016/S0140-6736(22)01439-8.
MATTHAY M A, ARABI Y, ARROLIGA A C, et al. A new global definition of acute respiratory distress syndrome. Am J Respir Crit Care Med, 2024, 209(1): 37–47. doi: 10.1164/rccm.202303-0558WS.
XU H, SHENG S, LUO W, et al. Acute respiratory distress syndrome heterogeneity and the septic ARDS subgroup. Front Immunol, 2023, 14: 1277161. doi: 10.3389/fimmu.2023.1277161.
VASSILIOU A G, KOTANIDOU A, DIMOPOULOU I, et al. Endothelial damage in acute respiratory distress syndrome. Int J Mol Sci, 2020, 21(22): 8793. doi: 10.3390/ijms21228793.
ABRAMS S T, ZHANG N, MANSON J, et al. Circulating histones are mediators of trauma-associated lung injury. Am J Respir Crit Care Med, 2013, 187(2): 160–169. doi: 10.1164/rccm.201206-1037OC.
YOKOYAMA Y, ITO T, YASUDA T, et al. Circulating histone H3 levels in septic patients are associated with coagulopathy, multiple organ failure, and death: a single-center observational study. Thromb J, 2019, 17: 1. doi: 10.1186/s12959-018-0190-4.
JIANG P, JIN Y, SUN M, et al. Extracellular histones aggravate inflammation in ARDS by promoting alveolar macrophage pyroptosis. Mol Immunol, 2021, 135: 53–61. doi: 10.1016/j.molimm.2021.04.002. RADU M, CHERNOFF J. An in vivo assay to test blood vessel permeability. J Vis Exp, 2013(73): e50062. doi: 10.3791/50062.
BLONDONNET R, CONSTANTIN J M, SAPIN V, et al. A pathophysiologic approach to biomarkers in acute respiratory distress syndrome. Dis Markers, 2016, 2016: 3501373. doi: 10.1155/2016/3501373.
MEYER N J, FERGUSON J F, FENG R, et al. A functional synonymous coding variant in the IL1RN gene is associated with survival in septic shock. Am J Respir Crit Care Med, 2014, 190(6): 656–664. doi: 10.1164/rccm.201403-0586OC.
OPAL S M, FISHER C J, DHAINAUT J F, et al. Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase Ⅲ, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group. Crit Care Med, 1997, 25(7): 1115-1124. doi:10.1097/00003246-199707000-00010.
AGRAWAL A, MATTHAY M A, KANGELARIS K N, et al. Plasma angiopoietin-2 predicts the onset of acute lung injury in critically ill patients. Am J Respir Crit Care Med, 2013, 187(7): 736–742. doi: 10.1164/rccm.201208-1460OC.
PAN B, LI Y, LIU Y, et al. Circulating CitH3 is a reliable diagnostic and prognostic biomarker of septic patients in acute pancreatitis. Front Immunol, 2021, 12: 766391. doi: 10.3389/fimmu.2021.766391.
HAYASE N, DOI K, HIRUMA T, et al. Damage-associated molecular patterns in intensive care unit patients with acute liver injuries: a prospective cohort study. Medicine (Baltimore), 2018, 97(41): e12780. doi: 10.1097/MD.0000000000012780.
ALLAM R, KUMAR S V R, DARISIPUDI M N, et al. Extracellular histones in tissue injury and inflammation. J Mol Med (Berl), 2014, 92(5): 465–472. doi: 10.1007/s00109-014-1148-z.
ALHAMDI Y, ABRAMS S T, CHENG Z, et al. Circulating histones are major mediators of cardiac injury in patients with sepsis. Crit Care Med, 2015, 43(10): 2094–2103. doi: 10.1097/CCM.0000000000001162.
LI Y, WAN D, LUO X, et al. Circulating histones in sepsis: potential outcome predictors and therapeutic targets. Front Immunol, 2021, 12: 650184. doi: 10.3389/fimmu.2021.650184.
TIAN Y, LI P, WU Z, et al. Citrullinated histone h3 mediates sepsis-induced lung injury through activating caspase-1 dependent inflammasome pathway. Front Immunol, 2021, 12: 761345. doi: 10.3389/fimmu.2021.761345.
FU S, YU S, ZHAO Y, et al. Unfractionated heparin attenuated histone-induced pulmonary syndecan-1 degradation in mice: a preliminary study on the roles of heparinase pathway. Inflammation, 2022, 45(2): 712–724. doi: 10.1007/s10753-021-01578-w.
LIU Y, MU S, LI X, et al. Unfractionated heparin alleviates sepsis-induced acute lung injury by protecting tight junctions. J Surg Res, 2019, 238: 175–185. doi: 10.1016/j.jss.2019.01.020.
Refbacks
- There are currently no refbacks.



